Tenivasc Tablet 5 mg+20 mg
Tenivasc Tablet 5 mg+20 mg Uses, Dosage, Side Effects, Food Interaction and all others data.
| Trade Name | Tenivasc Tablet 5 mg+20 mg |
| Generic | Amlodipine Besilate + Olmesartan Medoxomil |
| Weight | 5 mg+20 mg |
| Type | Tablet |
| Therapeutic Class | Combined antihypertensive preparations |
| Manufacturer | UniMed UniHealth Pharmaceuticals Ltd. |
| Available Country | Bangladesh |
| Last Updated: | October 19, 2023 at 6:27 am |
Uses
Indicated for the treatment of hypertension alone or with other antihypertensive agents, to lower blood pressure. This combination drug is indicated as initial therapy in patients likely to need multiple antihypertensive agents to achieve their blood pressure goals. The decision to use a combination ... Read moreDosage
Tenivasc Tablet 5 mg+20 mg dosage
Substitute individually titrated components for patients on Amlodipine and Olmesartan Medoxomil. This combination may also be given with increased amounts of Amlodipine, Olmesartan Medoxomil, or both, as needed.Initial therapy: Initiate with 5/20 mg once daily for 1 to 2 weeks and titrate as needed up to a maximum of 10/40 mg once daily. Due to decreased clearance of Amlodipine among elderly patients the recommended starting dose of Amlodipine is 2.5 mg in patients 75 years. The lowest dose of the combination is 5/20 mg; therefore, initial therapy with this combination drug is not recommended in patients >75 years old.Side Effects
The most common side effects include peripheral edema, headache, flushing, and dizziness. It can also cause Intestinal problems known a sprue-like enteropathy.Precaution
Amlodipine and Olmesartan Medoxomil combination should be used with caution because there is a risk for- Hypotension in volume- or salt depleted patients. Vasodilation in patients with severe aortic stenosis. Increased frequency, duration or severity of angina or acute Ml in patients with severe obstructive coronary artery disease.Interaction
The antihypertensive effect of angiotensin II receptor antagonists, including Olmesartan Medoxomil may be attenuated by NSAIDs including selective COX-2 inhibitors. Blood pressure, renal function and electrolytes should be closely monitored in patients on combination therapy and other agents that affect the RAS.Pregnancy & Breastfeeding use
Pregnancy Category D. Amlodipine and Olmesartan Medoxomil combination should not be used in 2nd and 3rd trimester because it can cause fetal death. When pregnancy is detected this combination should be discontinued as soon as possible. It is not known whether Olmesartan and Amlodipine are excreted in human milk. Because of the potential for adverse effects on the nursing infant, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.Contraindication
Cannot be co-administered with Aliskiren in patients with diabetes.Special Warning
Pediatric use: The safety and effectiveness have not been established in pediatric patients.Geriatric use: No overall differences in safety or effectiveness were observed between subjects 65 years of age or older and younger subjects.Renal impairment: There are no studies in patients with renal impairment.Hepatic impairment: Initial therapy is not recommended in hepatically impaired patients.Acute Overdose
There is no information on over dosage in humans.Storage Condition
Do not store above 30°C. Keep away from light and out of the reach of children.Innovators Monograph
You find simplified version here Tenivasc Tablet 5 mg+20 mg
